news

Roche to present new data on 27 different medicines at ASCO

Posted: 14 May 2014 | | No comments yet

Roche announced that new data on nine approved and 18 investigational medicines will be presented during the 50th American Society of Clinical Oncology Annual Meeting…

Roche logo

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data on nine approved and 18 investigational medicines will be presented during the 50th American Society of Clinical Oncology (ASCO) Annual Meeting. Of the more than 320 abstracts on Roche medicines, more than 40 have been accepted for oral presentation during the ASCO Annual Meeting.

“Since the first ASCO annual meeting 50 years ago, we are proud to have contributed practice-changing advances for people with a broad range of tumors including breast, blood, colorectal, lung, and skin cancers,” said Sandra Horning, Chief Medical Officer and Head, Global Product Development. “Data from 9 approved and 18 investigational medicines, such as our anti-PDL1 immunotherapy, at ASCO this year demonstrate our continued commitment to improve outcomes for people with cancer.”

The data to be presented at ASCO show the depth and strength of Roche’s oncology pipeline and include the following highlights:

Cancer Immunotherapy: A phase 1 study of anti-PDL1 in advanced bladder cancer will be presented in an oral session on Saturday 31 May. The presentation will feature important updates including; overall response rate, biomarker and safety information. As part of Roche’s global development plan to explore the potential of multiple immunotherapy targets in oncology, anti-PDL1 represents Roche’s most advanced investigational cancer immunotherapy in development.

Hematology: In addition to data from Roche’s anti-CD20 medicines MabThera/Rituxan (rituximab) and Gazyva (obinutuzumab), new data from two investigational medicines will be presented for the first time at ASCO. These data include interim results of a phase 1b study of the Bcl-2 inhibitor GDC-0199/ABT-199 in combination with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia and results of a phase 2 study of polatuzumab vedotin, an anti-CD79b antibody drug conjugate in relapsed/refractory non-Hodgkin lymphoma.

Overview of key presentations featuring Roche medicines